Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics.

Geographical Growth and Opportunities Scenario?

The Geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (Row).

The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.

Expected Growth For Viral Inactivation Market – The Global Viral Inactivation Market is expected to grow at a CAGR of 12.3% to reach $ 573.0 million.

Download PDF (Viral Inactivation): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121427017

Major Market Key Players in Viral Inactivation Market?

Acquisition and expansions were the two most important growth strategies employed by the key players in this market.

Major players in the Viral Inactivation Market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

SGS Life Science Services completed the expansion of biologics testing facility in Glasgow, UK. The 500 square meter expansion, with a staff of 45 personnel will offer a full range of validated bioanalytical methods for testing of biologics, viral vaccines, and gene & cell therapies.

Get 10% Customization on Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121427017